Chemical Biology Program
The Derek Tan Lab
The identification of small-molecule probes and therapeutic lead compounds to address novel biological targets is a significant current challenge in chemical biology and drug discovery. We are engaged in a two-pronged approach to this problem involving diversity-oriented synthesis and rational design as complementary approaches to ligand discovery. Our work in both of these areas is influenced at multiple levels by insights from natural products. At the core of these efforts is the development of new chemical methodologies to provide flexible, efficient, systematic access to these structures. We leverage multidisciplinary collaborations with biologists to evaluate these molecules to probe key biological processes and to explore new therapeutic opportunities in cancer and infectious diseases. Our group is strongly committed to promoting diversity and inclusion at all levels and welcomes scientists from all backgrounds!
Development of a p-hydroxybenzyl-alcohol-linked glutamate prodrug for activation by Pseudomonas carboxypeptidase G2.
Lee, J. P.; Corless, B. C.; Gardner, T. J.; Scheinberg, D. A.; Tan, D. S.* Org. Lett. 2023, in press.
[ Abstract | PubMed ]
Derek Tan, PhD
Chair, Chemical Biology Program, SKI; Tri-Institutional Professor; Eugene W. Kettering Chair
- Derek Tan’s lab studies diversity-oriented synthesis and rational drug design of probes and lead compounds for chemical biology and drug discovery.
- BS, Stanford University
- PhD, Harvard University
- Development of salicyl-AMS, a novel antibacterial agent to treat tuberculosis and other infections
- Louise and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2010)
- Dean's Award for Excellence in Teaching and Mentoring, Weill Cornell Graduate School of Medical Sciences (2013)
To learn more about available postdoctoral opportunities, please visit our Career Center
To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Derek Tan discloses the following relationships and financial interests:
Intellectual Property Rights
CVS Caremark Corp
Equity; Intellectual Property Rights; Professional Services and Activities
Institute for Research of Barcelona
Professional Services and Activities
Merck & Co Inc.
Regeneron Pharmaceuticals, Inc.
Research Center for Molecular Medicine of the Austrian Academy of Sciences (CeMM)
Professional Services and Activities
Tri-Institutional Therapeutics Discovery Institute
Fiduciary Role / Position
United Health Group
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.